Showing results (411-420 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|March 31, 2019
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 studyMichael R Savona, Olatoyosi Odenike, Philip C Amrein, et al.
The Lancet. Haematology|August 25, 2019
Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysisSedina Lewis, Jessica Glen, Dalia Dawoud, et al.
The Lancet. Haematology|May 5, 2015
Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trialCaterina P Minniti, Alexander M Gorbach, Dihua Xu, et al.
The Lancet. Haematology|August 2, 2016
Economic burden of non-malignant blood disorders across Europe: a population-based cost studyRamon Luengo-Fernandez, Richeal Burns, Jose Leal
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The Lancet. Haematology|May 8, 2018
Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohortBrian M Feldman, Georges E Rivard, Paul Babyn, et al.
The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
The Lancet. Haematology|July 21, 2018
Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studiesMark P Little, Richard Wakeford, David Borrego, et al.
Pageof 73